DYNDyne Therapeutics, Inc.

Healthcare
$16.65+27% 1Y

Price

+27%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 12% of companies
12/100
Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for DYN today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. Our proprietary FORCE platform is designed to leverage the transferrin receptor 1, or TfR1, to deliver targeted therapeutics to muscle tissue and the central nervous system, or CNS. The FORCE platform utilizes an antigen-binding fragment antibody, or Fab, targeting TfR1 conjugated to a payload that we rationally design to target the genetic basis of the disease we are seeking to treat.

In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR

P/En/a
Market value$3.41B
1 year+27%
5 years+6.7%

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 4, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Sep 29, 2026On September 29, 2026, the Company issued a press release and presentation announcing additional one-year clinical data from the ACHIEVE trial evaluating z-basivarsen in individuals with DM1.Regulation FD disclosure · Form 8-K
  2. Jul 29, 2026Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
  3. Jul 22, 2026On July 21, 2026, Dyne Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Jefferies LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

On our screens:Most shorted stocks

Biotechnology

Ranks #72 of 196 by RyuScore

Compare peers
GPCR-0.58%
Structure Therapeutics Inc.
QURE+0.22%
uniQure N.V.
ARQT+8.5%
Arcutis Biotherapeutics, Inc.
BEAM+4.6%
Beam Therapeutics Inc.
IDYA+0.21%
IDEAYA Biosciences, Inc.
ELVN+0.94%
Enliven Therapeutics, Inc.